On January 30, 2026, Life Biosciences — a biotech company co-founded by Harvard genetics professor David Sinclair — received FDA clearance to begin the first-ever human clinical trial of a cellular reprogramming technology. The trial targets two age-related vision diseases: glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). But the implications extend well beyond eye care.
This is the first time the FDA has cleared a test of partial epigenetic reprogramming in humans — a technique that its proponents argue doesn't just treat disease but reverses the biological aging that causes it.
At the World Governments Summit in Dubai in February 2026, Sinclair declared: "We are about to test, for the first time in history, whether we can reverse aging and cure diseases."
What Epigenetic Reprogramming Actually Means
To understand what is being tested, you need to understand how Sinclair frames aging itself. He calls it the "Information Theory of Aging": the idea that aging is not caused by irreversible genetic damage but by the progressive loss of correct epigenetic information — the chemical "tags" on DNA that tell cells which genes to activate and which to silence.
He likened the process to scratches on a CD. The underlying data — the music of youth — is still there. The scratches just prevent it from being read correctly. "Scientists have found ways to 'polish' the biological system and restore cellular function," Sinclair said.
The technique uses three of the four "Yamanaka factors" — proteins discovered by Nobel Prize-winning Japanese scientist Shinya Yamanaka that can fully reset a mature cell to a stem-cell-like state. Life Biosciences' innovation, developed over years of research, uses only three of the four (OCT4, SOX2, and KLF4 — excluding c-Myc) to partially reprogram cells. The goal is to restore youthful epigenetic patterns without erasing the cell's identity — its memory of what type of cell it is.
In a landmark 2020 study published in Nature, Sinclair's team used this three-factor approach to restore vision in a mouse model of glaucoma. More recently, the company's drug candidate ER-100 showed successful results in non-human primates, demonstrating improved neuronal regeneration in a monkey eye disease model — the kind of primate data that preceded FDA clearance for the human trial.
What the Phase 1 Trial Is Testing — and What It Is Not
The trial's drug, ER-100, will be injected directly into the eye of patients with glaucoma or NAION, targeting damaged retinal ganglion cells to deliver "rejuvenation instructions" directly to the affected tissue.
The primary endpoint is safety — not longevity extension. Researchers need to establish that the gene therapy does not cause tumors, immune reactions, or other serious adverse events. A secondary goal is to see whether some vision restoration occurs.
This distinction is important. As MIT Technology Review noted in its coverage of the trial, not all scientists agree that "reprogramming really counts as age reversal" — and critics have pushed back on the framing that this trial is a test of aging reversal itself. The Phase 1 design tells you whether the approach is safe; it cannot tell you whether human aging can be reversed systemically.
By June 2026, Sinclair had announced plans to also enter a broader whole-body rejuvenation drug into the XPRIZE Healthspan competition, expanding the scope of what his team is pursuing clinically.
The Scientific Debate Behind the Headlines
Sinclair is one of the most prominent — and polarizing — figures in longevity science. His previous claims about sirtuins and resveratrol generated years of research excitement before the evidence base proved more limited than he suggested. A 2024 Wall Street Journal investigation described him as a "reverse-aging guru" whose companies "have not panned out."
The epigenetic reprogramming field, however, is built on more substantial ground. The Yamanaka factors work — that is not contested. The open question is whether partial reprogramming, as opposed to full pluripotency, can be safely and reliably applied to adult human tissue at scale, across organs other than the eye, without oncogenic risk.
Researchers at the 2nd World Congress on Targeting Longevity in Berlin in April 2026 framed the moment precisely: the field is moving from "searching for a single anti-aging intervention" toward understanding aging as "a progressive loss of coordination between biological systems." Epigenetic reprogramming is one of the most credible candidates for addressing that loss — but the human evidence is, as yet, a single Phase 1 safety trial.
What This Means for Patients Right Now
Nothing about this trial changes what is currently available to patients. No approved epigenetic reprogramming therapy exists. No one should seek out or pay for experimental reprogramming outside of a formal clinical trial setting.
What the FDA clearance does signal is this: the foundational science has been rigorous enough, in animal and primate models, for the agency to allow its first human test. The results of that trial — particularly its interim safety data — will be one of the most closely watched findings in longevity science over the next 12 to 24 months.
